References
- Geller NL. Design of phase I and II clinical trials in cancer: A statistician's view. Cancer Invest 1984; 2: 483–491
- Rozencweig M, Dodion P, Nicaise C, . Approach to phase I trials in cancer patients. New Approaches in Cancer Therapy, H. Cortes Funes, M Rozencweig, et al. Raven Press, New York 1982; 1–13
- Woolley PV, Schein PS. Clinical pharmacology and phase I trial design. Methods of Cancer Research, V. DeVita, H. Busch. Academic Press, New York 1979; 177–198
- Owens AH. Predicting anticancer drug effects in man from laboratory animal studies. J Chron Dis 1963; 15: 223–228
- Penta JS, Rozencweig M, Guarino AM, et al. Mouse and large-animal toxiciology studies of twelve antitumor agents: Relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol 1979; 3: 97–101
- Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966; 50: 219–244
- Homan ER. Quantitative relationships between toxic doses of anti-tumor chemotherapeutic agents in animals and man. Cancer Chemother Rep 1972; 3: 13–19
- Goldsmith MA, Slavik M, Carter SK. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 1975; 35: 1354–1364
- Rozencweig M, Von Hoff DD, Staquet MJ, et al. Animal toxicology for early clinical trials with anticancer agents. Am J Clin Oncol 1981; 4: 21–28
- Marsoni S, Hurson S, Simon R, et al. Prediction of toxicity (t) in phase I (PI) anticancer drug trials by the National Cancer Institute (NCI) preclinical toxicology protocol (NPTP). Proc Am Assoc Cancer Res 1984; 25: 168
- Schneiderman MA. Mouse to man. Statistical problem in bringing a drug to clinical trial. Proc of he Fifth Berkeley Symposium on Mathematical Statistics and Probability. University of California Press, Berkeley 1967; Vol. 4: 855–866
- Muggia FM, Selawry OS, Hansen HH. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4, 6-0-2-thenylidene-P-D-glucopyramside) (NSC-122819). Cancer Chemother Rep 1971; 55: 575–581
- Hansen HH, Selawry OS, Muggia FM, et al. Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) (NSC 79037). Cancer Res 1971; 31: 223–227
- Staquet MJ, Rozencweig M, Von Hoff DD, Muggia FM. The delta and epsilon errors in the assessment of cancer clinical trials. Cancer Treat Rep 1979; 63: 1917–1921